A long-awaited study addressing the role of ivermectin in the battle against SARS-CoV-2 has just been published in the peer-reviewed American Journal of Therapeutics.
According to the study’s abstract, Dr. Tess Lawrie (MBBCh, PhD), a medicinal evidence expert, and her team “assessed the efficacy of ivermectin treatment in reducing mortality, in secondary outcomes, and in chemoprophylaxis, among people with, or at high risk of, COVID-19 infection.”
**IVERMECTIN NEWS**We cannot emphasize enough the global significance of this newly published paper.
It provides the highest possible systematic review and meta-analysis for #ivermectin that leaves NO doubt whatsoever that IVM’s global adoption must be immediately implemented. https://t.co/W3ePN3EKbH
— Frontline Covid-19 Critical Care (@Covid19Critical) June 20, 2021
Ivermectin, an anti-parasitic drug with both antiviral and anti-inflammatory properties, has been used by doctors around the world as both a treatment and a prophylactic for COVID-19, the disease caused by SARS-CoV-2.
As governments and public health officials attempted to find solutions to the pandemic as it unfolded, some doctors and scientists turned to trusted, though repurposed, medications—a practice that is not unusual when faced with a new or unexpected situation.
Despite its safety and available anecdotal evidence, critics of the drug’s use were quick to point out a lack of peer-reviewed studies using ivermectin to treat the viral infection and resulting disease.
In response to the criticisms and resulting attack on the use of ivermectin by Big Tech, Big Pharma, and public health organizations around the world, Dr. Lawrie and her team looked at bibliographic databases up to April 25 of this year. The authors “sifted for studies, extracted data, and assessed risk of bias” before conducting a meta-analyses resulting in the inclusion of 24 randomized control trials involving a total of 3,406 participants.
The study’s authors conclude that “large reductions in COVID-19 deaths are possible using ivermectin.” The safe and cost effective drug “is likely to have a significant impact on the SARS-CoV-2 pandemic globally.”
Dr. Lawrie told TrialSite:
“We are overjoyed to have the product of months of hard work finally published! And what a wonderful author team – it’s been an honour to work with people of such high integrity, who maintained a spirit of hope and optimism in spite of all the difficulties with which we have been confronted. Thank you for not giving up! Now the authorities have all the evidence they need to approve ivermectin immediately.”
A similar conclusion has also been reached by several expert groups from the UK, Italy, Spain, US, and a group from Japan headed by the Nobel Prize-winning discoverer of ivermectin, professor Satoshi Omura.
The study also mirrors what has been observed in other studies “from Bangladesh and India to Peru and Argentina; from Israel and Nigeria to the ICON study in South Florida and population-wide public health initiatives using ivermectin from Mexico City to Uttar Pradesh, India,” reports TrialSite News.
Despite increasing censorship of ivermectin across Big Tech social media platforms and search engines, the response to the study on social media has largely been positive and continues to grow.
JUST PUBLISHED! ????The definitive review on ivermectin – it works – now let's use it! https://t.co/svG8tcBHXg
— BIRD Group (@BIRDGroupUK) June 19, 2021
Extremely rigorous and conservative analysis of 15 separate trials concludes that Ivermectin reduces Covid mortality. This information should lead to more trials, this time in courtrooms.https://t.co/QsNi4Dy4su
— Chris Martenson (@chrismartenson) June 20, 2021
This meta-analysis of Ivermectin effectiveness is just now peer reviewed and published. The evidence of prophylactic effectiveness is particularly important. https://t.co/FKT3zETmtw
— Bret Weinstein (@BretWeinstein) June 20, 2021
A Cochrane-standard (=highest) review and meta-analysis of Ivermectin against Covid-19 by Bryant-Lawrie, now peer-reviewed and published, concludes that the evidence justify the global adoption.https://t.co/7gSGUKp6mY pic.twitter.com/DKN3UiT391
— Covid19Crusher (@Covid19Crusher) June 19, 2021
Nobody can say no to #ivermectin anymore. 62% death risk reduction. 86% infection risk reduction. Peer reviewed. Published in the American Journal of Therapeutics. Hats off to Dr Tess Lawrie and team! @BIRDGroupUK @Covid19Critical @afriforum https://t.co/bYCYIq6OVE
— Barend Petrus Uys (@bpuys6) June 19, 2021
Awareness of ivermectin’s efficacy and its adoption by physicians around the world to successfully treat COVID-19 continues to accelerate.